OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 12:07:17 2025-06-18 am EDT			5-day change	1st Jan Change
1.015 ^AUD	+6.84%		+3.57%	-57.71%

May. 25	Oncosil Medical Says A$8.7M Capital Raise At Issue Price A$0.003 Per Share	RE
May. 21	Oncosil Medical Seeks Trading Halt	RE

OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director

Published on 08/30/2024 at 01:00

OncoSil Medical Limited refered to the announcement on 15 July 2024 regarding the appointment of Peter Hall as Non-Executive Director. Peter has advised that, due to unforeseen personal family issues that require his immediate attention, he has reluctantly delayed joining the board of OncoSil until 1 October 2024.

Latest news about OncoSil Medical Limited

Oncosil Medical Says A$8.7M Capital Raise At Issue Price A$0.003 Per Share	May. 25	RE
Oncosil Medical Seeks Trading Halt	May. 21	RE
OncoSil Medical Said Analysis Shows Better Survival for Pancreatic Cancer Patients Treated with Therapy Device	May. 07	MT
OncoSil Medical Limited Announces Changes to Company Secretary, Effective April 1, 2025	Mar. 31	CI
Oncosil Medical Appoints Shelley Steyn As CFO	Mar. 17	RE
ASX Small-Cap Stocks to Watch	Mar. 17	MT
Oncosil Announces CFO Changes	Mar. 17	CI
Oncosil Announces Resignation of Christian Dal Cin as Company Secretary, Effective Date Is March 31, 2025	Mar. 17	CI
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2024	Feb. 25	CI
OncoSil Medical Says 120 German Hospitals Secure Authorization to Negotiate Fee for Cancer Treatment Device; Shares Surge 40%	Feb. 03	MT
OncoSil Medical Receives Medical Device Regulation Certification; Shares Surge 20%	Jan. 28	MT
OncoSil Medical Limited Announces the Appointment of Lel Smits as a Non- Executive Director to the Board	Jan. 14	CI
ASX Biggest Losers	Jan. 08	MT
ASX Biggest Gainers	Jan. 06	MT
ASX Biggest Gainers	Jan. 01	MT
OncoSil Medical Randomizes First South Australia Patient in Pancreatic Cancer Clinical Trial; Shares Up 17%	Dec. 30	MT
OncoSil Medical Signs Exclusive Distribution Agreements in Nordics Region, Egypt	Nov. 17	MT
OncoSil Medical Secures UK Conformity Assessed Renewal Certificates for Cancer Treatment Device; Shares Up 8%	24-10-20	MT
OncoSil Medical Secures Distribution Deal for Pancreatic Cancer Therapy in Middle East; Shares Drop 7%	24-10-06	MT
Peter Hall Elects Not to Join Oncosil Medical Limited's Board	24-09-29	CI
OncoSil Medical Achieves Milestones in Two Pancreatic Cancer Trials; Shares Up 8%	24-09-26	MT
OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director	24-08-30	CI
OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2024	24-08-29	CI
OncoSil's Commercial Treatment Sales Surge 78% in Fiscal Q4; Shares Up 10%	24-08-14	MT
OncoSil Medical Gets AU$2.7 Million Investment for Building Distribution Network	24-07-25	MT

Chart OncoSil Medical Limited

Duration

Period

OSL: Dynamic Chart

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Employees

Sector

Pharmaceuticals

Calendar

Jul. 07 - Extraordinary Shareholders Meeting

More about the company